Adherencija pacijenata na terapiji anti-TNF monoklonskim protutijelima

professional thesis

• Author: Katarina Miličević
• Mentor: Vesna Bačić Vrca (mentor)
• Committee member: Ivana Marinović (predsjednik povjerenstva)
• Committee member: Vesna Bačić Vrca (član povjerenstva)
• Committee member: Srećko Marušić (član povjerenstva)
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Centre for applied pharmacy); Zagreb
• Defense date and country: 2023-09-29, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract

Biološki lijekovi anti-TNF (engl. tumor necrosis factor TNF) monoklonska protutijela,
primjenjuju se u liječenju različitih autoimunih upalnih bolesti poput reumatoidnog artritisa,
ankilozatnog spondilitisa, Chronove bolesti, ulceroznog kolitisa. Važna u liječenju svih bolesti,
adherencija ima poseban značaj u liječenju ovih bolesti budući da loša adherencija pacijenta
može dovesti do nepovratnog oštećenja zahvaćenih struktura.
Cilj ovog specijalističkog rada je pregledom dostupne i relevantne literature utvrditi razinu
adherencije pacijenata na terapiji anti-TNF monoklonskim protutijelima, istražiti čimbenike
utjecaja na neadherentnost te procijeniti moguću ulogu farmaceuta u poboljšanju adherencije.
Prilikom izrade ovog rada pretraživana je baza podataka PubMed, stručna literatura, službene
stranice Europske i Hrvatske agencije za lijekove i medicinska pomagala (EMA, HALMED), te
drugi raspoloživi izvori.
Temeljem rezultata publiciranih studija može se zaključiti da je razina adherencije pacijenata na
anti-TNF monoklonskim protutijelima vrlo visoka te da ovi pacijenti imaju poboljšanje
kvalitete života, što ima utjecaj i na ukupno smanjenje troškova u zdravstvenom sustavu, budući
izostaje dodatno liječenje i pridruženi novi troškovi.
Čimbenici koji smanjuju adherenciju su negativna uvjerenja pacijenata o učinkovitosti liječenja
i nuspojave terapije.
Budući se veliki dio anti-TNF monoklonskih protutijela izdaje na recept, savjetodavna uloga
javnog ljekarnika je važna i može doprinijeti boljoj adherentnosti pacijenata.

Abstract (english)

Biological drugs anti-TNF monoclonal antibodies are used in the treatment of various
autoimmune inflammatory diseases, such as rheumatoid arthritis, ankylosing spondylitis,
Crohn's disease, ulcerative colitis. Important in the treatment of all diseases, adherence has a
special significance in the treatment of these diseases, since poor patient adherence can lead to
irreversible damage to the affected structures.
The aim of this specialized paper is to determine the level of adherence of patients on anti-TNF
monoclonal antibody therapy by reviewing the available and relevant literature, to investigate
factors affecting non-adherence, and to assess the possible role of pharmacists in improving
adherence.
During the preparation of this work, the PubMed database, professional literature, official
websites of the European and Croatian Agency for Medicines and Medical Devices (EMA,
HALMED) and other available sources were searched.
Based on the results of published studies, it can be concluded that the level of adherence of
patients to anti-TNFmonoclonal antibodies is very high and that these patients have an
improvement in their quality of life, which also has an impact on the overall reduction of costsin
the healthcare system, since there is no additional treatment and associated new costs. Factors
that reduce adherence are patients' negative beliefs about the effectiveness of treatment and side
effects of therapy.
Since a large part of anti-TNF monoclonal antibodies is issued by prescription, the advisory role
of public pharmacists is important and can contribute to better patient adherence.

• Keywords: adherencija; suradljivost; farmaceutska skrb; biološka terapija; monoklonska protutijela; etanercept; adalimumab; infliksimab; golimumab; cetrolizumab pegol
• Keywords (english): adherence; compliance; pharmaceutical care; biological therapy; monoclonal antibodies; etanercept; adalimumab; infliximab; golimumab; cetrolizumab pegol
• Language: croatian
• URN:NBN: urn:nbn:hr:163:445587
• Study programme: Title: Clinical pharmacy; Study programme type: university; Study level: postgraduate specialist; Academic / professional title: sveučilišni/a magistar/sveučilišna magistra kliničke farmacije (sveučilišni/a magistar/sveučilišna magistra kliničke farmacije)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2024-02-02 10:46:41